D-0838-2020 Class III Terminated

Recalled by Macleods Pharma Usa Inc — Plainsboro, NJ

FDA drug recall D-0838-2020 was initiated by Macleods Pharma Usa Inc on Jan 24, 2020 and is designated Class III. Reason for recall: Subpotent Drug: Out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride Tablets. The recall status is terminated (terminated Dec 16, 2022). Affected quantity: 4694 30x60-count bottles.

Recall details

Product Type
Drugs
Report Date
Feb 12, 2020
Initiation Date
Jan 24, 2020
Termination Date
Dec 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4694 30x60-count bottles

Product description

Pioglitazone and Metformin Hydrochloride Tablets, USP 15 mg/500 mg, Rx Only, 60-count bottle, Manufactured for Macleods Pharma USA, Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, India, NDA 33342-176-09

Reason for recall

Subpotent Drug: Out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride Tablets.

Distribution pattern

Nationwide

Code information

Lot# BPA5903A, EXP 05/2021; BPA5819A, EXP 11/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0838-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0838-2020. Report a data issue: hello@regdatalab.com.